open access

Vol 62, No 4 (2012)
Review paper
Published online: 2012-09-01
Get Citation

Fractionated CyberKnifeTM stereotactic radiotherapy for patients with prostate cancer: presentation of the method

Grzegorz Głowacki, Dawid Bodusz, Wojciech Majewski, Małgorzata Stąpór-Fudzińska, Aleksandra Grządziel, Ewa Chawińska, Łukasz Michalecki, Leszek Miszczyk
Nowotwory. Journal of Oncology 2012;62(4):274-282.

open access

Vol 62, No 4 (2012)
Review article
Published online: 2012-09-01

Abstract

A significant technological development of radiotherapy in the last several years has enabled the implementation in
daily practice of highly specialized procedures for accurate imaging and precise irradiation for patients with prostate
cancer.
Due to the numerous reports on the low value of the alpha/beta ratio for prostate cancers, using such technology
gives an opportunity to implement hypofractionated radiotherapy safely.
This article presents the first Polish implementation of CyberKnifeTM based stereotactic radiotherapy for prostate
cancer patients.

Eligibility for treatment includes low risk prostate cancer patients with good performance status and biopsy confirmed prostate cancer. Preparing the patient for IGRT procedures includes transrectal implantation of golden markers and patient immobilization using a vacuum pillow.
Treatment planning was based on the fusion of computed tomography and magnetic resonance imaging. Verification of prostate position was performed by localization of implanted markers using two orthogonal kilovoltage beams and detectors.
The dose of 7.25 Gy per fraction to a total dose of 36.25 Gy was used to irradiate the prostate tumor with a margin. The organs at risk are rectum, bladder, femoral heads and the urethra.
A comparative analysis of the doses used in conventional and hypofractionated radiation therapy after estimation as the normalized total dose (NTD) and the biologically effective dose (BED) was made.
Estimation of the risk of adverse effects in healthy tissues, both for acute and late reactions, justifies using stereotactic fractionated radiotherapy for patients suffering from prostate cancer.
Reduction of total treatment time is justified from an economic as well as an ethical point of view.

Abstract

A significant technological development of radiotherapy in the last several years has enabled the implementation in
daily practice of highly specialized procedures for accurate imaging and precise irradiation for patients with prostate
cancer.
Due to the numerous reports on the low value of the alpha/beta ratio for prostate cancers, using such technology
gives an opportunity to implement hypofractionated radiotherapy safely.
This article presents the first Polish implementation of CyberKnifeTM based stereotactic radiotherapy for prostate
cancer patients.

Eligibility for treatment includes low risk prostate cancer patients with good performance status and biopsy confirmed prostate cancer. Preparing the patient for IGRT procedures includes transrectal implantation of golden markers and patient immobilization using a vacuum pillow.
Treatment planning was based on the fusion of computed tomography and magnetic resonance imaging. Verification of prostate position was performed by localization of implanted markers using two orthogonal kilovoltage beams and detectors.
The dose of 7.25 Gy per fraction to a total dose of 36.25 Gy was used to irradiate the prostate tumor with a margin. The organs at risk are rectum, bladder, femoral heads and the urethra.
A comparative analysis of the doses used in conventional and hypofractionated radiation therapy after estimation as the normalized total dose (NTD) and the biologically effective dose (BED) was made.
Estimation of the risk of adverse effects in healthy tissues, both for acute and late reactions, justifies using stereotactic fractionated radiotherapy for patients suffering from prostate cancer.
Reduction of total treatment time is justified from an economic as well as an ethical point of view.

Get Citation
About this article
Title

Fractionated CyberKnifeTM stereotactic radiotherapy for patients with prostate cancer: presentation of the method

Journal

Nowotwory. Journal of Oncology

Issue

Vol 62, No 4 (2012)

Article type

Review paper

Pages

274-282

Published online

2012-09-01

Bibliographic record

Nowotwory. Journal of Oncology 2012;62(4):274-282.

Authors

Grzegorz Głowacki
Dawid Bodusz
Wojciech Majewski
Małgorzata Stąpór-Fudzińska
Aleksandra Grządziel
Ewa Chawińska
Łukasz Michalecki
Leszek Miszczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl